Cardiovascular

Latest News

Effect of Remote Patient Monitoring on Stage 2 Hypertension

Effect of Remote Patient Monitoring on Stage 2 Hypertension

By Lyle Dennis, MD
Irina Koyfman, DNP, NP-C, RN

May 6th 2025

A community-based remote patient monitoring (RPM) program was associated with significant reduction in blood pressure in Medicare patients with stage 2 hypertension, highlighting the potential benefits of RPM with care coaching.

Q&A with Sid Patel, MD

Abelacimab Demonstrates Safety and Efficacy for Patients With AFib of All Ages: Sid Patel, MD

By Kyle Munz
Siddharth M. Patel, MD, MPH

April 24th 2025

One's ZIP code can greatly influence care access | image credit: Syda Productions - stock.adobe.com

"The Barriers Are Real": Antoine Keller, MD, on Geography and Cardiovascular Health

By Kyle Munz
Antoine Keller, MD, FACC, FACS

April 18th 2025

Jeremy Wigginton, MD

Lp(a) and Getting a Head Start Against Heart Disease: Jeremy Wigginton, MD

By Kyle Munz
Jeremy Wigginton, MD

April 8th 2025

ACC.25

High-Impact Trials at ACC.25 Signal Shift in Chronic Disease Treatment

By Giuliana Grossi
Christian Ruff, MD

April 4th 2025

Lipoprotein(a) and Cardiovascular Risk

Learn about more about lipoprotein(a), including how to improve patient outcomes through better screening and management.

Continuing Medical Education

Exploring Transthyretin-Mediated Amyloidosis and Its Phenotypes: A Comprehensive Approach to Patient Treatment

1.5 Credits / Cardiology, Neurology, Rare Diseases

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology

Evidence-Based Guidelines Point to Leap in Care for Hypertrophic Cardiomyopathy

1.0 Credit / Cardiology

More News

March 11th 2018

Secondhand Smoke and Screen Time: Prevention Insights at ACC

Coverage from the 67th Scientific Session of the American College of Cardiology.

March 11th 2018

A Champion of Women's Heart Health Tells How the Journey Starts With Better Data

The journey to better women's heart health starts with having more data, said Nanette Kass Wenger, MD, MACC, MACP, FAHA, professor of cardiology at Emory University School of Medicine, during the Simon Dack Keynote Lecture, which opened the 67th Scientific Session of the American College of Cardiology.

March 6th 2018

Music Makes a Difference During Cardiac Stress Tests, Study Finds

The study will be presented during the 67th American College of Cardiology Scientific Session in Orlando, Florida.

March 1st 2018

Several Walks a Week Can Protect Women From Heart Failure After Menopause

A study being presented at the upcoming meeting of the American College of Cardiology found a dose–response relationship between walking and reduced heart failure risk.

Higher BMI Associated With Increased Risk of CVD, Greater Proportion of Life Lived With CVD

March 1st 2018

Higher BMI Associated With Increased Risk of CVD, Greater Proportion of Life Lived With CVD

Jaime Rosenberg

Adults with obesity have an earlier onset of incident CVD, a greater proportion of life lived with CVD morbidity, and shorter overall survival compared with adults with normal BMI; and the proportion of adults with incident CVD events was significantly higher in adults who were classified as overweight or obese compared with adults with normal BMI, according to a study in JAMA Cardiology.

Early Look at ACC Navigator Program Shows Inpatient Mortality Drops as Hospitals Take Positive Steps

February 26th 2018

Early Look at ACC Navigator Program Shows Inpatient Mortality Drops as Hospitals Take Positive Steps

In the next phase of the program, researchers will dig into the data they have gathered so far to identify the best practices for reducing 30- and 90-day readmission rates.

MedPAC Reports Lower Readmission Rates and Reduced Medicare Spending With HRRP

February 9th 2018

MedPAC Reports Lower Readmission Rates and Reduced Medicare Spending With HRRP

Surabhi Dangi-Garimella, PhD

According to the Medicare Payment Advisory Commission (MedPAC), hospital readmission rates have fallen following implementation of the Hospital Readmissions Reduction Program (HRRP), and HRRP did not have a negative impact on mortality rates.

Genetic Testing a Must for Relatives of Cardiomyopathy Patients

February 5th 2018

Genetic Testing a Must for Relatives of Cardiomyopathy Patients

With 4 in 10 cardiomyopathies having genetic links, there is a need for relatives of patients with cardiomyopathy to be screened in order to prevent early death, according to a recent study published in European Heart Journal.

Catheter Ablation More Effective Than Traditional Therapy in Atrial Fibrillation

February 3rd 2018

Catheter Ablation More Effective Than Traditional Therapy in Atrial Fibrillation

Samantha DiGrande

A new study published in the February issue of the New England Journal of Medicine found that patients that received radiofrequency catheter ablation compared with traditional drug therapies for atrial fibrillation (AF) had significantly lower hospitalization and mortality rates.

Higher Resting Heart Rate Associated With Adverse CV, Non-CV Events

February 1st 2018

Higher Resting Heart Rate Associated With Adverse CV, Non-CV Events

Jaime Rosenberg

Higher resting heart rate (HR) and increases in HR over time are associated with increased risk of adverse cardiovascular (CV) and non-CV events, such as incident heart failure and all-cause mortality, according to a study published in JAMA Cardiology.

February 1st 2018

Treatment-Free Remission and Preventing Cardiotoxicity: The Future of CML Care

Surabhi Dangi-Garimella, PhD

Coverage from the 59th Annual Meeting and Exposition of the American Society of Hematology, December 9-12, 2017.

Prime Therapeutics, Boehringer-Ingelheim Reach Outcomes-Based Contract for Jardiance

January 30th 2018

Prime Therapeutics, Boehringer-Ingelheim Reach Outcomes-Based Contract for Jardiance

Empagliflozin (Jardiance) and another SGLT2 inhibitor, canagliflozin (Invokana) have been competing aggressively; both have clinical trial results showing cardiovascular benefits.

January 25th 2018

ODYSSEY Outcomes Results for Sanofi's Praluent to Lead Off ACC Meeting

The annual meeting of the American College of Cardiology (ACC), which runs March 10-12, 2018, in Orlando, Florida, will open with cardiovascular outcomes results for the PCSK9 inhibitor alirocumab (Praluent). The meeting also features updates on anti-inflammatory drugs, the use of SGLT2 inhibitors in heart failure, and how cardiology is shifting to new healthcare delivery models.

Study Finds Prior Authorization Mandates for PCSK9 Drugs Raise Questions of Access

January 20th 2018

Study Finds Prior Authorization Mandates for PCSK9 Drugs Raise Questions of Access

Researchers were especially concerned about barriers for patients with familial hypercholesterolemia, whose needs would seem clear cut but who nonetheless faced costly hurdles, such as genetic testing.

January 17th 2018

A Cost-Effectiveness Analysis of Cardiology eConsults for Medicaid Patients

Daren Anderson, MD Victor Villagra, MD Emil N. Coman, PhD Ianita Zlateva, MPH Alex Hutchinson, MBA Jose Villagra, BS J. Nwando Olayiwola, MD, MPH

A randomized trial of eConsults for cardiology referrals from primary care resulted in significant reductions in total cost of care compared with traditional face-to-face consultations.

Dr Amar Bhakta on Changing the Approach to Treating Heart Failure

January 13th 2018

Dr Amar Bhakta on Changing the Approach to Treating Heart Failure

Reimbursement structures and population demographics change the way hospitals approach heart failure, explained Amar Bhakta, MD, of Rush University Medical Center.

Chronic Inflammation, Dyslipidemia Puts Children, Teens With HIV at Higher CV Risk, Study Finds

January 12th 2018

Chronic Inflammation, Dyslipidemia Puts Children, Teens With HIV at Higher CV Risk, Study Finds

The same mechanisms that cause those with long-term HIV infection to suffer higher rates of heart attacks or strokes put children born with disease at early risk of cardiovascular disease, according to a new study.

CMS Unveils New Voluntary Bundled Payment Model

January 10th 2018

CMS Unveils New Voluntary Bundled Payment Model

The announcement comes after CMS canceled an Obama-era proposal for mandatory bundled payments in cardiac care, as well as a mandatory expansion of a program in joint replacements.

CMS Unveils New Voluntary Bundled Payment Model

January 10th 2018

CMS Unveils New Voluntary Bundled Payment Model

The announcement comes after CMS canceled an Obama-era proposal for mandatory bundled payments in cardiac care, as well as a mandatory expansion of a program in joint replacements.

New Cholesterol Test More Accurate Than Old Test That Requires Fasting

January 3rd 2018

New Cholesterol Test More Accurate Than Old Test That Requires Fasting

Laura Joszt, MA

A newer method for calculating low-density lipoprotein (LDL) cholesterol is more accurate than the older method that required people fast before blood was drawn.

December 26th 2017

Perspectives of a Lipidologist: LDL Cholesterol Testing, PCSK9 Inhibitors

Dr Todd Hobbs Discusses Identifying and Removing Barriers to Care for Obesity

December 21st 2017

Dr Todd Hobbs Discusses Identifying and Removing Barriers to Care for Obesity

Although patients and physicians both recognize the need to discuss obesity, the lack of resources, time, and expertise often prevents physicians for offering care and patients from asking for it, explained Todd Hobbs, MD, Novo Nordisk’s vice president and chief medical officer.

Conference Stories That Captivated AJMC® Readers in 2017

December 21st 2017

Conference Stories That Captivated AJMC® Readers in 2017

Samantha DiGrande

In 2017, The American Journal of Managed Care® (AJMC®) covered conferences on a range of topics: oncology, diabetes, managed care, and much more. however, the most-read coverage from conferences that AJMC® attended mostly focused on cardiology trial results, particularly the cardiovascular results of diabetes medications.

Dr Jay Edelberg Discusses Results of Alirocumab by Race and Ethnicity

December 21st 2017

Dr Jay Edelberg Discusses Results of Alirocumab by Race and Ethnicity

Trial results have shown that alirocumab (Praluent) is safe and effective across patient populations, said Jay Edelberg, MD, PhD, vice president and head of Cardiovascular Development and Cardiovascular Affairs at Sanofi.

December 19th 2017

The CVD-Real Trial: What Can Real-World Evidence Tell Us About Primary Prevention?

An interview with one of the authors of a large observational study that has seen findings consistent with recent cardiovascular outcomes trials in SGLT2 inhibitors.

Improved Recommendations of Deintensification in Clinical Guidelines Is Needed

December 19th 2017

Improved Recommendations of Deintensification in Clinical Guidelines Is Needed

Laura Joszt, MA

Currently, clinical guidelines offer little guidance on deintensifying care, which is critical for balancing overuse and underuse of services.

December 18th 2017

As Trials Report Cardiovascular Outcomes Data, What About Microvascular Results?

Evidence is more robust on kidney function but not sufficient to make drug decisions, one expert said. A whole separate trial, called CREDENCE, is examining renal function in patients taking canagliflozin.

Dr Amar Bhakta Explains a New Pathway to Prevent Heart Failure Readmissions

December 17th 2017

Dr Amar Bhakta Explains a New Pathway to Prevent Heart Failure Readmissions

A new pathway uses a multidisciplinary team to help reduce 30-day heart failure readmissions, explained Amar Bhakta, MD, of Rush University Medical Center.

December 14th 2017

For Those With Diabetes and CV Risk, Personalized Care Matters

Robert A. Gabbay, MD, PhD, FACP

From the Editor in Chief

December 13th 2017

MGH: Centralized population health coordinators help improve care for patients with chronic disease

...

9 10 11 12 13 14 15 16 17

...

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions